[{"id":"710fbbdc-56f1-402d-9817-416d903d4d64","acronym":"SUPβORT","url":"https://clinicaltrials.gov/study/NCT07000305","created_at":"2025-06-07T14:45:31.114Z","updated_at":"2025-06-07T14:45:31.114Z","phase":"Phase 2","brief_title":"A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer","source_id_and_acronym":"NCT07000305 - SUPβORT","lead_sponsor":"Tao Zhang","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/20/2025","start_date":" 05/20/2025","primary_txt":" Primary completion: 05/20/2027","primary_completion_date":" 05/20/2027","study_txt":" Completion: 05/20/2028","study_completion_date":" 05/20/2028","last_update_posted":"2025-06-02"},{"id":"fa2b9899-956d-4a45-a9c3-8729c5d6b741","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856447","created_at":"2025-09-07T01:48:31.731Z","updated_at":"2025-09-07T01:48:31.731Z","phase":"Phase 1","brief_title":"The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer","source_id_and_acronym":"NCT06856447","lead_sponsor":"toqa saad mohammed mohammed","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 05/20/2025","primary_completion_date":" 05/20/2025","study_txt":" Completion: 01/10/2026","study_completion_date":" 01/10/2026","last_update_posted":"2025-03-04"},{"id":"59848edf-80f8-486e-a558-b5247dba69ec","acronym":"HEPATOXALI","url":"https://clinicaltrials.gov/study/NCT06649474","created_at":"2025-02-26T10:15:50.734Z","updated_at":"2025-02-26T10:15:50.734Z","phase":"","brief_title":"Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1","source_id_and_acronym":"NCT06649474 - HEPATOXALI","lead_sponsor":"University Hospital, Clermont-Ferrand","biomarkers":" HMGB1","pipe":"","alterations":" ","tags":["HMGB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/06/2024","start_date":" 09/06/2024","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-10-18"},{"id":"4f28ce0c-9a5a-4a61-b5dd-312c3d0839fe","acronym":"KEYNOTE-A10","url":"https://clinicaltrials.gov/study/NCT03058289","created_at":"2021-01-18T15:03:51.688Z","updated_at":"2025-02-25T14:37:17.876Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","source_id_and_acronym":"NCT03058289 - KEYNOTE-A10","lead_sponsor":"Intensity Therapeutics, Inc.","biomarkers":" MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2024-08-13"},{"id":"07559a56-04b6-451e-84a1-341907a657e2","acronym":"LOGiC","url":"https://clinicaltrials.gov/study/NCT00680901","created_at":"2021-01-18T02:32:43.490Z","updated_at":"2024-07-02T16:34:26.181Z","phase":"Phase 3","brief_title":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","source_id_and_acronym":"NCT00680901 - LOGiC","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • capecitabine • oxaliplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 545","initiation":"Initiation: 06/04/2008","start_date":" 06/04/2008","primary_txt":" Primary completion: 09/24/2012","primary_completion_date":" 09/24/2012","study_txt":" Completion: 01/22/2025","study_completion_date":" 01/22/2025","last_update_posted":"2024-06-13"},{"id":"1b5c72eb-5c58-41c6-a2fd-22f00febc998","acronym":"","url":"https://clinicaltrials.gov/study/NCT06002789","created_at":"2023-08-21T14:09:01.504Z","updated_at":"2024-07-02T16:35:20.355Z","phase":"Phase 2","brief_title":"Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC","source_id_and_acronym":"NCT06002789","lead_sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","biomarkers":" MSI • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-02-07"},{"id":"0f94f327-5d1e-4729-af10-466de3a55ceb","acronym":"METIMMOX-2","url":"https://clinicaltrials.gov/study/NCT05504252","created_at":"2022-08-17T13:55:01.719Z","updated_at":"2024-07-02T16:35:21.848Z","phase":"Phase 2","brief_title":"METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin","source_id_and_acronym":"NCT05504252 - METIMMOX-2","lead_sponsor":"University Hospital, Akershus","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-01-30"},{"id":"8acd0062-77ba-4a71-84a2-fa85ca8c8018","acronym":"METIMMOX","url":"https://clinicaltrials.gov/study/NCT03388190","created_at":"2021-01-18T16:43:21.943Z","updated_at":"2024-07-02T16:35:21.888Z","phase":"Phase 2","brief_title":"METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin","source_id_and_acronym":"NCT03388190 - METIMMOX","lead_sponsor":"University Hospital, Akershus","biomarkers":" PTEN • CRP","pipe":"","alterations":" ","tags":["PTEN • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/29/2018","start_date":" 05/29/2018","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-01-30"},{"id":"c99a638b-6c3f-48fe-94bc-75e6982749f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01387295","created_at":"2021-01-18T05:41:32.025Z","updated_at":"2024-07-02T16:35:26.593Z","phase":"Phase 2","brief_title":"Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease","source_id_and_acronym":"NCT01387295","lead_sponsor":"Dorte Nielsen","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 05/01/2017","primary_completion_date":" 05/01/2017","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2023-12-11"},{"id":"e32a87b6-7193-4a78-a806-d31027dab74d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02428101","created_at":"2021-01-18T11:36:57.221Z","updated_at":"2024-07-02T16:35:27.965Z","phase":"","brief_title":"Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer","source_id_and_acronym":"NCT02428101","lead_sponsor":"Ain Shams University","biomarkers":" ABCG2","pipe":"","alterations":" ","tags":["ABCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 80","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-11-28"},{"id":"d3fbe9fc-cb0c-4ea4-a0c8-0aaa88366b82","acronym":"TUD-APOLLO-064","url":"https://clinicaltrials.gov/study/NCT02688140","created_at":"2022-03-24T01:54:02.216Z","updated_at":"2024-07-02T16:35:30.678Z","phase":"Phase 3","brief_title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02688140 - TUD-APOLLO-064","lead_sponsor":"Technische Universität Dresden","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • arsenic trioxide • mercaptopurine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-11-02"},{"id":"b74b934a-6330-471e-a832-f62d2f6e245f","acronym":"RAIC","url":"https://clinicaltrials.gov/study/NCT05307198","created_at":"2023-05-25T23:05:07.006Z","updated_at":"2024-07-02T16:35:34.169Z","phase":"Phase 2","brief_title":"Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC","source_id_and_acronym":"NCT05307198 - RAIC","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" FLT3LG","pipe":"","alterations":" ","tags":["FLT3LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 04/25/2024","primary_completion_date":" 04/25/2024","study_txt":" Completion: 04/25/2025","study_completion_date":" 04/25/2025","last_update_posted":"2023-10-09"},{"id":"5bd83935-3470-48d6-bfc6-3106a9241234","acronym":"IROCAS","url":"https://clinicaltrials.gov/study/NCT02967289","created_at":"2023-09-05T21:09:27.475Z","updated_at":"2024-07-02T16:35:38.167Z","phase":"Phase 3","brief_title":"IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting","source_id_and_acronym":"NCT02967289 - IROCAS","lead_sponsor":"UNICANCER","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 792","initiation":"Initiation: 03/27/2017","start_date":" 03/27/2017","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2023-09-04"},{"id":"dabf61c3-90e1-4c7b-b51c-3e0495df0ca9","acronym":"OSCAR","url":"https://clinicaltrials.gov/study/NCT02885753","created_at":"2021-01-18T14:09:51.809Z","updated_at":"2024-07-02T16:35:39.698Z","phase":"Phase 3","brief_title":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver","source_id_and_acronym":"NCT02885753 - OSCAR","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" KRAS • NRAS • RAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • RAS mutation • KRAS exon 2 mutation","tags":["KRAS • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • RAS mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2023-08-17"},{"id":"afcfd4b5-b9b7-4935-b5b3-933797806160","acronym":"OCEAN","url":"https://clinicaltrials.gov/study/NCT04416490","created_at":"2021-01-18T21:17:08.716Z","updated_at":"2024-07-02T16:35:41.581Z","phase":"","brief_title":"Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer","source_id_and_acronym":"NCT04416490 - OCEAN","lead_sponsor":"Boryung Pharmaceutical Co., Ltd","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/25/2020","start_date":" 03/25/2020","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-07-28"},{"id":"d4b8682b-1c56-42e4-a0d8-dc1a45eb1425","acronym":"ENSEMBLE","url":"https://clinicaltrials.gov/study/NCT05646511","created_at":"2022-12-12T15:00:16.382Z","updated_at":"2024-07-02T16:35:46.746Z","phase":"Phase 3","brief_title":"Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE)","source_id_and_acronym":"NCT05646511 - ENSEMBLE","lead_sponsor":"National Cancer Center Hospital East","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1 • UGT1A1 wild-type","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1 • UGT1A1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 608","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2023-05-31"},{"id":"400078f7-64d4-4277-9022-f03050a00674","acronym":"","url":"https://clinicaltrials.gov/study/NCT00840177","created_at":"2021-01-29T06:59:12.815Z","updated_at":"2024-07-02T16:35:49.076Z","phase":"Phase 2","brief_title":"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia","source_id_and_acronym":"NCT00840177","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 12/10/2009","start_date":" 12/10/2009","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 10/21/2021","study_completion_date":" 10/21/2021","last_update_posted":"2023-05-03"},{"id":"5bf6cf0e-af40-421b-841d-dd34d155f1a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05624138","created_at":"2022-11-21T14:57:16.184Z","updated_at":"2024-07-02T16:35:50.769Z","phase":"Phase 3","brief_title":"The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","source_id_and_acronym":"NCT05624138","lead_sponsor":"Tanta University","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/09/2022","start_date":" 11/09/2022","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-04-12"},{"id":"eaedf424-b580-4215-9d78-fcafabf11730","acronym":"CAREME","url":"https://clinicaltrials.gov/study/NCT05699746","created_at":"2023-01-26T15:02:43.157Z","updated_at":"2024-07-02T16:35:56.907Z","phase":"Phase 3","brief_title":"CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD","source_id_and_acronym":"NCT05699746 - CAREME","lead_sponsor":"Zhejiang University","biomarkers":" MSH6 • MSH2","pipe":"","alterations":" ","tags":["MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-01-26"},{"id":"ee9d2948-e174-4b7d-b507-9603eb76e47b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05476432","created_at":"2022-07-27T13:54:36.196Z","updated_at":"2024-07-02T16:35:59.364Z","phase":"Phase 3","brief_title":"HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study","source_id_and_acronym":"NCT05476432","lead_sponsor":"Sun Yat-sen University","biomarkers":" TYMS","pipe":"","alterations":" ","tags":["TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/26/2022","start_date":" 07/26/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2022-12-09"},{"id":"07fd8cef-c29a-413c-862a-1abe2245a21c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05510856","created_at":"2022-08-26T13:58:43.138Z","updated_at":"2024-07-02T16:36:02.090Z","phase":"Phase 4","brief_title":"Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients","source_id_and_acronym":"NCT05510856","lead_sponsor":"Tanta University","biomarkers":" HMOX1 • NEFL","pipe":"","alterations":" ","tags":["HMOX1 • NEFL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2022-10-20"},{"id":"4aeac741-dc8b-4ecd-92aa-103a4963e4a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05158621","created_at":"2021-12-15T13:53:37.950Z","updated_at":"2024-07-02T16:36:02.296Z","phase":"","brief_title":"A Screening Study Targeting Tumor-specific Antigens","source_id_and_acronym":"NCT05158621","lead_sponsor":"Gritstone bio, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 08/15/2022","study_completion_date":" 08/15/2022","last_update_posted":"2022-10-18"},{"id":"c59140a0-25cc-462a-8fa0-14d8fcd877e6","acronym":"AuspiCiOus","url":"https://clinicaltrials.gov/study/NCT05177133","created_at":"2022-01-04T13:53:42.957Z","updated_at":"2024-07-02T16:36:03.789Z","phase":"Phase 2","brief_title":"Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)","source_id_and_acronym":"NCT05177133 - AuspiCiOus","lead_sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","biomarkers":" HER-2 • IFNG • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • HER-2 negative • IFNG expression","tags":["HER-2 • IFNG • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • HER-2 negative • IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/05/2021","start_date":" 11/05/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/04/2029","study_completion_date":" 11/04/2029","last_update_posted":"2022-09-16"},{"id":"4a96be15-3189-42fb-8719-80265307cf12","acronym":"","url":"https://clinicaltrials.gov/study/NCT05494320","created_at":"2022-08-09T17:04:59.070Z","updated_at":"2024-07-02T16:36:05.790Z","phase":"","brief_title":"the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin","source_id_and_acronym":"NCT05494320","lead_sponsor":"Ain Shams University","biomarkers":" ABCC2","pipe":"","alterations":" ","tags":["ABCC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/15/2021","start_date":" 08/15/2021","primary_txt":" Primary completion: 08/05/2022","primary_completion_date":" 08/05/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-08-09"}]